Prolight Diagnostics Delivers on SBRI Healthcare Grant
Prolight Diagnostics (“Prolight”) today announces that its subsidiary Psyros Diagnostics (“Psyros”) has successfully completed the SBRI Healthcare phase 2 award, accelerating development of its unique digital immunoassay. Psyros received the SBRI Healthcare phase 2 grant of approximately 1 million GBP last year, requiring the completion of certain milestones. Psyros has now met or exceeded all […]
Prolight Diagnostics shows proof-of-performance for high-sensitive immuno assay
Prolight Diagnostics (“Prolight”) today announced that its subsidiary Psyros Diagnostics (“Psyros”) has been able to demonstrate proof-of-performance that its high-sensitivity immunoassay is capable of reproducibly detecting low levels of specific proteins in a digital manner. “This is a very important step on our journey to develop a high-sensitivity assay for digitally detecting troponin. Such an […]
Prolight Diagnostics signs commercialisation agreement for PLD Micro Flex
Prolight Diagnostics AB today announces that it has signed a commercialisation agreement for its proprietary point-of-care (POC) platform PLD Micro Flex with its technology and development partner, The Technology Partnership plc (TTP), in Cambridge, UK. Under the agreement, TTP will pursue further development and ongoing external initiatives and discussions with the aim of securing an […]
Annual General Meeting of Prolight Diagnostics AB (publ) on 20 May 2022
The Annual General Meeting (AGM) of Prolight Diagnostics AB (publ) took place on Friday 20 May 2022. The AGM was conducted by way of postal voting, without the physical presence of shareholders. Full information regarding the decisions of the AGM is available on the companys website, www.prolightdiagnostics.se. Resolution regarding the adoption of the income statement […]
Prolight Diagnostics AB acquires Psyros Diagnostics Ltd
Prolight Diagnostics AB has today signed an agreement to acquire UK-based Psyros Diagnostics Ltd for 65 MSEK (ca. £5.25M). Psyros Diagnostics has developed a ground-breaking single-molecule counting Point-of-Care (POC) technology. This patent-pending and multiplex-capable technology enables the measurement of biomarkers at extremely low concentrations (femtomolar 10-15) in approximately 10 minutes or less. “To our knowledge, […]
